Signal transduction pathways controlled by reversible tyrosine phosphorylation have been implicated in the regulation of a variety of synaptic and cellular functions in neurons, with both protein tyrosine kinases (PTKs) and phosphatases (PTPs) playing crucial roles under normal and pathophysiological conditions [1] . The ability to modulate such signal transduction pathways selectively holds enormous therapeutic potential for a number of conditions. To date, much of the drug development focus has been on protein kinases. The first drugs directed against PTKs have now entered the market, representing breakthroughs in cancer therapy [1] . Nevertheless, these approaches have their limitations and novel therapeutic targets and strategies are required to complement kinase-directed drug development. Despite the importance of the phosphatases in the control of reversible phosphorylation-dependent signal transduction, these enzymes remain underexploited as therapeutic targets [1] .
The protein tyrosine phosphatase PTP1B plays a wellestablished role in down regulating signaling in response to insulin and leptin and is a highly validated therapeutic target for diabetes and obesity [1] . Furthermore, PTP1B also plays a positive role in promoting signaling events associated with breast tumorigenesis and is a therapeutic target for HER2-positive cancer [1] . Now, a recent study has extended the scope of PTP1B-directed therapeutics to include anxiety disorders, highlighting the potential for PTP1B inhibitors to be exploited as anxiolytics [2] .
In this study, Qin et al.
[2] investigated signaling changes in the amygdala, focusing on endocannabinoid (eCB) signaling as a regulator of anxiety. They noted that facilitation of eCB signaling reverses anxiety induced by chronic stress, whereas disruption of eCB signaling promotes states of anxiety. Considering that production of eCB is regulated by metabotropic glutamate receptors, in particular mGluR5, which may be subject to regulation by reversible tyrosine phosphorylation, they proposed that a decrease in mGluR5 tyrosine phosphorylation could impair eCB production and signaling. In a previous study, the authors reported that the LIM domain only protein LMO4 functioned as an inhibitor of PTP1B, which exerted its effects by increasing the oxidation and inactivation of the phosphatase [3] . Now, they noted a profound anxiety phenotype in mice that were deficient in LMO4 expression in glutaminergic neurons. This led them to propose that in response to chronic stress, mediated by glucocorticoids, LMO4-mediated inhibition of PTP1B was impaired, which in turn led to a PTP1B-catalyzed decrease in tyrosine phosphorylation of mGluR5 and the collapse of eCB production, resulting in increased anxiety. Although this is an attractive model, not least because of the potential therapeutic implications of inhibiting PTP1B as a strategy for treatment of anxiety disorders, closer scrutiny of the data reveals that several aspects of the study require further validation.
LMO4 as a regulator of PTP1B
Central to the model is the regulation of PTP1B by LMO4, a Zinc finger motif protein that has been implicated in protein-protein interactions. PTP1B-null mice are healthy, display enhanced insulin sensitivity, do not develop type 2 diabetes and are resistant to obesity when fed with a high fat diet. This is associated with the ability of PTP1B to dephosphorylate the insulin receptor b-subunit and the leptin receptor-associated JAK2 tyrosine kinase, thereby down regulating insulin and leptin signaling [1] . Here, Qin et al. noted that ablation of LMO4 in neurons resulted in an obesity phenotype, and was associated with impaired leptin-induced phosphorylation of STAT3, together with insulin resistance, impaired glucose homeostasis and attenuated central leptin signaling. They interpreted this phenotype as resulting from the relief of an LMO4-mediated inhibitory constraint on PTP1B [3] .
The mechanism they propose involves manipulating redox regulation of PTP1B function. It is now established that the controlled production of reactive oxygen species (ROS), in particular hydrogen peroxide, represents a mechanism for fine-tuning tyrosine phosphorylation-dependent signaling in response to a variety of stimuli. Members of the PTP family are characterized by a signature motif, HC(X) 5 R(S/T), in which the catalytically essential, invariant cysteine is exquisitely sensitive to reversible oxidation and inactivation. Consequently, stimulus-induced production of H 2 O 2 , such as in response to insulin or leptin, leads to the transient oxidation and inactivation of those PTPs,
